Acumen Pharmaceuticals (ABOS) BofA Securities 2025 Healthcare Conference summary

Program overview and scientific rationale

• Sabirnetug is a monoclonal antibody targeting amyloid beta oligomers, believed to be the most toxic species in Alzheimer's pathology, aiming to neutralize their harmful effects on neurons.

• Targeting oligomers is considered distinct from approaches focusing on monomers or insoluble forms, with the goal of reducing neuronal dysfunction and related downstream effects.

Phase I Intercept AD study findings

• The phase I study in early Alzheimer's patients demonstrated a favorable safety profile, robust target engagement, and low ARIA rates compared to plaque-directed antibodies.

• First demonstration of native oligomer engagement in a phase I study, with dose-dependent target engagement observed in cerebrospinal fluid.

• High-dose cohorts showed a 20%-25% reduction in amyloid PET signal, comparable to leading agents.

• Strong biomarker responses were observed in CSF and plasma, including improvements in synaptic markers, supporting confidence in the drug's mechanism.

• No clear cognitive signal was expected or observed due to limited dosing and study design.

Phase II Altitude AD study and future plans

• Phase II Altitude AD enrolled 542 patients across 80 sites in five countries within 10 months, reflecting strong interest and momentum.

• The study uses iADRS as the primary cognitive endpoint over 18 months, with CDR-SB and biomarker assessments as secondary measures.

• No interim or futility analyses are planned to maintain study integrity, aiming for pivotal evidence.

• Subcutaneous formulation of sabirnetug is being developed in parallel with IV, with future integration options under consideration.